Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).

Trial Details

NCT ID
NCT03051464
Phase
PHASE2 / PHASE3
Sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Complete responders and Non-complete responders
  • Chemoradiation + EBRT Boost
  • Chemoradiation + HDRBT Boost
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Québec, Quebec, Canada|46.81228,-71.21454

Key Eligibility Criteria

  • Rectal cancer patients, clinically staged as T2-T3a,b N0-1 by MRI or endoscopic/trans-rectal ultrasound
  • Rectal cancer staged as N0-1 by MRI or EUS/TRUS
  • No metastatic lesion
  • Rectal tumor occupying less than half of the circumference

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →